Jiuzhou Pharmaceutical's 2026 interim net profit at 387 million yuan, down 26.33% year-on-year

Earnings
โดย Jiemian·Read original
Summary · why it matters

Jiuzhou Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company at 387 million yuan, a decrease of 26.33% compared to the same period last year. Total operating revenue was 2.575 billion yuan, down 10.30% year-on-year. Net cash flow from operating activities was 553 million yuan, down 34.52% year-on-year. The latest asset-liability ratio stands at 15.76%, gross margin at 36.89%, ROE at 4.35%, and diluted earnings per share at 0.44 yuan.

Impact on stocks 1

Others▼ · 1 stocks
© 2026 MarketDXNews